SK Telecom Co. Ltd. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? SK Telecom Co. Ltd. Common Stock trades at $34.56 (market cap $13.36B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: SK Telecom Co. Ltd. Common Stock is the larger of the two by market cap, and SK Telecom Co. Ltd. Common Stock pays a 2.85% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold SK Telecom Co. Ltd. Common Stock for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SKM | XBI | |
|---|---|---|
Market Cap | $13.36B | $10.11B |
Volume | 1,302,042 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $46.00 | $169.55 |
52-Week Low | $19.68 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $19.41B | — |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Trailing returns across standard periods
SK Telecom is a South Korean telecommunications company providing mobile, broadband, and digital services. It also develops services in areas such as AI, cloud, and data centers.
Read more on SKM →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →